1.The efficacy and safety of high-frequency irreversible electroporation for benign prostatic hyperplasia: a randomized controlled open-label multicenter trial
Liang DONG ; Zhen TONG ; Benkang SHI ; Qianyuan ZHUANG ; Yuanwei LI ; Min GONG ; Xiaoming XU ; Shengcai ZHOU ; Xulai TAO ; Xinxing DU ; Haifeng WANG ; Jian HUANG ; Wei XUE
Chinese Journal of Urology 2025;46(3):161-165
Objective:To investigate the efficacy and safety of high-frequency irreversible electroporation (H-FIRE) in treating benign prostatic hyperplasia (BPH).Methods:This randomized controlled open-label multicenter clinical trial enrolled patients from nine medical centers in China between August 2020 and July 2022. Inclusion criteria: age 50–80 years, International Prostate Symptom Score (IPSS) ≥12, maximum urinary flow rate (Q max) >5 ml/min and ≤15 ml/min. Exclusion criteria: prostate malignancy, contraindications to surgery or anesthesia. Patients were randomized 1∶1 into the H-FIRE group (experimental) or the control group (daily oral 0.2 mg tamsulosin hydrochloride sustained-release capsules). Primary outcomes included Q max, IPSS, prostate volume, and International Index of Erectile Function-5 (IIEF-5) scores, measured at baseline, 1 and 3 months post-treatment. Results:A total of 160 cases were included in this study, including 80 cases in the experimental group and 80 cases in the control group, 30 cases in Renji Hospital, 7 cases in Qilu Hospital of Shandong University, 8 cases in Tongji Hospital, 3 cases in Hunan Provincial Hospital, 13 cases in Shanghai Pudong Hospital, 29 cases in Hwa Mei Hospital, 18 cases in Yiyuan County People's Hospital, and 38 cases in Shanghai East Hospital, and 14 cases in Sun Yat-sen Memorial Hospital. At 3 months of post-treatment, Q max in the experimental group increased by a median of 7.50 (3.55, 14.50) ml/s from the baseline value, whereas in the control group it increased by a median of 1.70 (-1.40, 6.00) ml/s, and the difference between the two groups was statistically significant ( P < 0.01, U = 1 083); and at 3 months of post-treatment, IPSS in the experimental group decreased by a median of 12.00 (7.00, 17.00) points in the test group and 6.00 (2.00, 11.00) points in the control group, and the magnitude of improvement in IPSS scores in the test group was significantly higher than that in the control group ( P < 0.01, U = 1 248); at 3 months of post-treatment, the prostate volume decreased by a median of 12.16 (5.69, 18.27) ml in the experimental group and 0 (-3.94, 6.89) ml in the control group, suggesting that H-FIRE significantly reduced prostate gland volume ( P<0.01, U=1 111). The difference in elevated IIEF-5 scores from baseline at 3 months of treatment between the experimental and control groups was not statistically significant[0(-2.00, 1.00) points vs. 0(-2.00, 1.50) points; P=0.54, U=2 338]. There were no serious adverse events in the two groups. Conclusions:H-FIRE could significantly improve both subjective and objective symptoms of BPH with a low risk of severe complications.
2.The efficacy and safety of high-frequency irreversible electroporation for benign prostatic hyperplasia: a randomized controlled open-label multicenter trial
Liang DONG ; Zhen TONG ; Benkang SHI ; Qianyuan ZHUANG ; Yuanwei LI ; Min GONG ; Xiaoming XU ; Shengcai ZHOU ; Xulai TAO ; Xinxing DU ; Haifeng WANG ; Jian HUANG ; Wei XUE
Chinese Journal of Urology 2025;46(3):161-165
Objective:To investigate the efficacy and safety of high-frequency irreversible electroporation (H-FIRE) in treating benign prostatic hyperplasia (BPH).Methods:This randomized controlled open-label multicenter clinical trial enrolled patients from nine medical centers in China between August 2020 and July 2022. Inclusion criteria: age 50–80 years, International Prostate Symptom Score (IPSS) ≥12, maximum urinary flow rate (Q max) >5 ml/min and ≤15 ml/min. Exclusion criteria: prostate malignancy, contraindications to surgery or anesthesia. Patients were randomized 1∶1 into the H-FIRE group (experimental) or the control group (daily oral 0.2 mg tamsulosin hydrochloride sustained-release capsules). Primary outcomes included Q max, IPSS, prostate volume, and International Index of Erectile Function-5 (IIEF-5) scores, measured at baseline, 1 and 3 months post-treatment. Results:A total of 160 cases were included in this study, including 80 cases in the experimental group and 80 cases in the control group, 30 cases in Renji Hospital, 7 cases in Qilu Hospital of Shandong University, 8 cases in Tongji Hospital, 3 cases in Hunan Provincial Hospital, 13 cases in Shanghai Pudong Hospital, 29 cases in Hwa Mei Hospital, 18 cases in Yiyuan County People's Hospital, and 38 cases in Shanghai East Hospital, and 14 cases in Sun Yat-sen Memorial Hospital. At 3 months of post-treatment, Q max in the experimental group increased by a median of 7.50 (3.55, 14.50) ml/s from the baseline value, whereas in the control group it increased by a median of 1.70 (-1.40, 6.00) ml/s, and the difference between the two groups was statistically significant ( P < 0.01, U = 1 083); and at 3 months of post-treatment, IPSS in the experimental group decreased by a median of 12.00 (7.00, 17.00) points in the test group and 6.00 (2.00, 11.00) points in the control group, and the magnitude of improvement in IPSS scores in the test group was significantly higher than that in the control group ( P < 0.01, U = 1 248); at 3 months of post-treatment, the prostate volume decreased by a median of 12.16 (5.69, 18.27) ml in the experimental group and 0 (-3.94, 6.89) ml in the control group, suggesting that H-FIRE significantly reduced prostate gland volume ( P<0.01, U=1 111). The difference in elevated IIEF-5 scores from baseline at 3 months of treatment between the experimental and control groups was not statistically significant[0(-2.00, 1.00) points vs. 0(-2.00, 1.50) points; P=0.54, U=2 338]. There were no serious adverse events in the two groups. Conclusions:H-FIRE could significantly improve both subjective and objective symptoms of BPH with a low risk of severe complications.
3.Observation on the effect of non-nutritive sucking on low birth weight infants
Youshu ZHOU ; Wenhui QI ; Shengcai HUANG ; Yinyu WANG
Chongqing Medicine 2017;46(34):4796-4798
Objective To study the effect of non-nutritional sucking intervention on low birth weight infants.Methods One hundred and forty cases of low birth weight infants were randomly divided into experimental group(n=73) and conventional group (n=67).Both groups of infants were treated with enteral nutrition.The experimental group was treated with non-nutritive sucking interventions.Results The abnormality rate of QRS wave(2.74%) and heart rate (4.11%) in experimental group were significantly lower than those in the conventional group (11.94 %,17.91 %),the differences were statistically significant (P< 0.05).In the experimental group,the meconium discharge time,recovery time,nasogastric tube indwelling time and the time of intestinal nutrition reached 481.4 kJ-1 · kg-1 · d-1 were significantly lower than that of the conventional group(P<0.05).The incidence of bloating(2.74 %),vomiting (2.74 %) and gastric retention (5.48 %) in experimental group were significantly lower than than of the conventional group (13.43%,11.94%,25.37%),P<0.05.There was no significant difference in the incidence of apnea and diarrhea between the two groups (P>0.05).Conclusion Non-nutritional sucking intervention can effectively reduce the incidence of ECG abnormalities and feeding complications in low birth weight infants.
4.A study on creating a promotion index system of medical quality in Grade Ⅲ hospitals in Beijing
Jun LI ; Baoli ZHOU ; Miaorong XIE ; Jiang QIAN ; Yabin YU ; Xiulan LI ; Dongxiang ZHENG ; Xiaoying LI ; Jinsheng ZHANG ; Ying WANG ; Kunling SHEN ; Shengcai HOU ; Xiangmei ZHAO ; Yutong ZHENG ; Yanghai CUI ; Jiang FENG ; Dongguo LIU ; Xiaosong LI ; Yong YAN
Chinese Journal of Hospital Administration 2011;27(4):254-257
To explore how to create and optimize a promotion index system of medical quality evaluation, this article focuses on the hospital visiting process from patients, using analyzing collected those index system from couples of Grade Ⅲ hospitals in Beijing, and combining the results of literal study, field study and specialist consult, according to the different situation of general hospitals and specially hospitals, with the spirit of "maintaining the patients benefits, safeguarding the patients safety,and enhancing the medical quality", introduces the framework of the promotion index system, the rules to select the indicator, and so on, and discusses several problerns related to creating the index system.
5.Research allicin allied with DDP on growth inhibition and induction apoptosis of rat bladder tumor
Journal of Chongqing Medical University 1987;0(01):-
Objective:To evaluate the validity of allicin allied with DDP on bearing tumor SD rats,explore the mechanisms of function.Methods:set up bladder cancer models by irrigating MNU into SD rat bladder,examine the incidence of cancer.At the end of 14th weeks,five groups were accepted peritoneal injection with NS,allicin,DDP,DDP + allicin respectively.one time every other day,every rat was injected 0.2ml different drugs every time,7 times in all,observe experimental animals life quality at the same time.After all rats were killed,bladders were weighed.Tumor tissues were embeded in paraffin,each sample was cut into 3 pieces for HE staining,and observed by light microscope.TUNEL method was applied to examine apoptosis of tumor cells.Results:in the DDP group,a marked decrease was shown in the appearance of weight when compared with the other groups.Apoptosis of bladder tumors occurred in all groups,especially in allicin allied with DDP groups.Conclusion:Allicin allied with DDP can inhibite bladder tumor growth by inducing apoptosis in common,and improve life quality.

Result Analysis
Print
Save
E-mail